10 minute read
May 16, 2024

AstraZeneca’s Oral, Selective CDK2 Inhibitor for the Treatment of CDK4/6 Inhibitor-Resistant Cancers and CCNE1-Amplified Tumors

AZD8421

oral selective CDK2 inhibitor Ph. I/II for advanced or metastatic solid tumors optimization from literature compounds AACR San Diego 2024, “New Drugs on the Horizon” AstraZeneca, Waltham, MA

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other molecules you may be interested in